Global Hematological Malignancies Market to Reach $71.6 Billion by 2030
The global market for Hematological Malignancies estimated at US$46.8 Billion in the year 2023, is expected to reach US$71.6 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2023-2030. Leukemia, one of the segments analyzed in the report, is expected to record a 7% CAGR and reach US$30.3 Billion by the end of the analysis period. Growth in the Lymphoma segment is estimated at 6.4% CAGR for the next 7-year period.
The U.S. Market is Estimated at $14.1 Billion, While China is Forecast to Grow at 5.7% CAGR
The Hematological Malignancies market in the U.S. is estimated at US$14.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$12.3 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 5.4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook